We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
Read MoreHide Full Article
Key Takeaways
Hims & Hers links patients to licensed providers with telehealth, records, e-scripts and fulfillment.
HIMS is investing in data and AI for smarter routing, better diagnosis and personalized care at scale.
HIMS adds pharma partnerships plus advanced diagnostics, multi-cancer detection tests and holistic Labs.
Hims & Hers Health, Inc. (HIMS - Free Report) has built its model around a tightly integrated digital platform that connects patients with licensed healthcare providers while managing the full care journey end-to-end. Its services combine telehealth consultations, electronic medical records, digital prescriptions and pharmacy fulfillment into a single, streamlined experience, enabling users to move seamlessly from diagnosis to treatment and ongoing care. The platform is designed to support personalized treatment plans and continuous engagement, with patients accessing services through web and mobile interfaces while providers deliver care remotely.
This technology-first approach is increasingly being enhanced through deeper investments in data and artificial intelligence (AI). HIMS has emphasized building a next-generation healthcare platform powered by AI to enable more intelligent routing, improved diagnosis and highly personalized care delivery at scale. By integrating data-driven tools across its ecosystem, Hims & Hers aims to standardize high-quality care while maintaining a tailored experience for individual users.
Recent developments further reinforce the role of the platform as the central connector between patients, providers and treatment access. Partnerships with pharmaceutical companies have expanded the availability of FDA-approved medications directly through the platform, while new offerings such as advanced diagnostics, multi-cancer early detection testing and holistic Labs experiences extend its capabilities beyond consultations into proactive and preventive care. Together, these initiatives deepen Hims & Hers’ platform’s role in linking patients to providers and a broader ecosystem of healthcare solutions in a more accessible and coordinated manner.
LifeMD, Inc. (LFMD - Free Report) leverages a vertically integrated digital platform to connect patients with providers through virtual consultations, diagnostics and pharmacy services, enabling a seamless end-to-end care experience. LifeMD facilitates continuous engagement via its nationwide provider network and proprietary technology infrastructure. Recently, LifeMD expanded its platform capabilities with the launch of Novo Nordisk’s oral Wegovy and the addition of Eli Lilly’s Foundayo, reinforcing its role in delivering accessible, technology-enabled care solutions to patients.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, operates a comprehensive technology platform that connects patients with providers across virtual, in-person and automated care settings, enabling integrated and efficient healthcare delivery. Amwell empowers health systems and payers to deliver hybrid care through its scalable, API-driven infrastructure and deep integrations with clinical workflows. Amwell has also extended its Digital First contract with the U.S. Defense Health Agency, highlighting its continued role in enabling seamless, technology-driven care for a large patient population.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 34.9% year to date, underperforming the industry’s decline of 27.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.6X is lower than the industry’s average of 3.2X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 15.1% improvement compared with 2025.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) has built its model around a tightly integrated digital platform that connects patients with licensed healthcare providers while managing the full care journey end-to-end. Its services combine telehealth consultations, electronic medical records, digital prescriptions and pharmacy fulfillment into a single, streamlined experience, enabling users to move seamlessly from diagnosis to treatment and ongoing care. The platform is designed to support personalized treatment plans and continuous engagement, with patients accessing services through web and mobile interfaces while providers deliver care remotely.
This technology-first approach is increasingly being enhanced through deeper investments in data and artificial intelligence (AI). HIMS has emphasized building a next-generation healthcare platform powered by AI to enable more intelligent routing, improved diagnosis and highly personalized care delivery at scale. By integrating data-driven tools across its ecosystem, Hims & Hers aims to standardize high-quality care while maintaining a tailored experience for individual users.
Recent developments further reinforce the role of the platform as the central connector between patients, providers and treatment access. Partnerships with pharmaceutical companies have expanded the availability of FDA-approved medications directly through the platform, while new offerings such as advanced diagnostics, multi-cancer early detection testing and holistic Labs experiences extend its capabilities beyond consultations into proactive and preventive care. Together, these initiatives deepen Hims & Hers’ platform’s role in linking patients to providers and a broader ecosystem of healthcare solutions in a more accessible and coordinated manner.
Hims & Hers is scheduled to report first-quarter 2026 results on May 11, after the closing bell.
LFMD & AMWL Enable Platform-Led Virtual Care
LifeMD, Inc. (LFMD - Free Report) leverages a vertically integrated digital platform to connect patients with providers through virtual consultations, diagnostics and pharmacy services, enabling a seamless end-to-end care experience. LifeMD facilitates continuous engagement via its nationwide provider network and proprietary technology infrastructure. Recently, LifeMD expanded its platform capabilities with the launch of Novo Nordisk’s oral Wegovy and the addition of Eli Lilly’s Foundayo, reinforcing its role in delivering accessible, technology-enabled care solutions to patients.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, operates a comprehensive technology platform that connects patients with providers across virtual, in-person and automated care settings, enabling integrated and efficient healthcare delivery. Amwell empowers health systems and payers to deliver hybrid care through its scalable, API-driven infrastructure and deep integrations with clinical workflows. Amwell has also extended its Digital First contract with the U.S. Defense Health Agency, highlighting its continued role in enabling seamless, technology-driven care for a large patient population.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 34.9% year to date, underperforming the industry’s decline of 27.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.6X is lower than the industry’s average of 3.2X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 15.1% improvement compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.